BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

66.13 (USD) • At close November 12, 2024
Bedrijfsnaam BioMarin Pharmaceutical Inc.
Symbool BMRN
Munteenheid USD
Prijs 66.13
Beurswaarde 12,603,253,790
Dividendpercentage 0%
52-weken bereik 65.35 - 99.56
Industrie Biotechnology
Sector Healthcare
CEO Mr. Jean-Jacques Bienaime M.B.A., MBA
Website https://www.biomarin.com

An error occurred while fetching data.

Over BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with

Vergelijkbare Aandelen

Viatris Inc. logo

Viatris Inc.

VTRS

12.93 USD

Insulet Corporation logo

Insulet Corporation

PODD

275.1 USD

Bio-Techne Corporation logo

Bio-Techne Corporation

TECH

74.41 USD

Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc.

ALNY

268.95 USD

Incyte Corporation logo

Incyte Corporation

INCY

80.58 USD

Henry Schein, Inc. logo

Henry Schein, Inc.

HSIC

67.46 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)